Latest from Corporate Social

Bloom43 is transforming breast surgery preparation with a prehabilitation platform that combines a wearable medical device and guided digital support. By strengthening tissue resilience before surgery and empowering patients through an 8-week companion program, Bloom43 is improving recovery, reducing complications, and redefining how modern surgical care begins, long before the first incision.

In an era of escalating regulatory restrictions on materials of concern, merely reacting to bans is no longer viable and causes immense financial and market share losses. Manufacturers possess significant advance warning through public registries, offering years to prepare before restrictions take effect. Shifting from reactive compliance to predictive analysis, proactively monitoring these signals and investing in early R&D for alternatives is crucial to avoid disruption, secure a competitive advantage, and lead through anticipated changes.

Screen time profoundly influences a child's developing brain, impacting attention, language, sleep, and emotional well-being. It's crucial to understand how digital experiences shape development and recognize that our own screen habits teach children what truly matters. By prioritizing balanced, intentional use and fostering real-world interactions, we can support their long-term growth.

VoxelGrids, backed by Zoho, has deployed India’s first indigenously designed and manufactured 1.5T MRI scanner at the Chandrapur Cancer Care Foundation near Nagpur. Built through over a decade of R and D, the system claims major cost advantages by eliminating liquid helium, and the company is now developing a containerised mobile MRI to expand diagnostic access in remote regions.

Emerald Cloud Lab (ECL) is revolutionizing life sciences research with its cloud-based, fully automated platform, enabling scientists to conduct experiments remotely without traditional lab spaces. By offering access to high-end instruments and automating routine tasks, ECL is democratizing research, accelerating scientific discovery, and expanding global collaboration. With plans to integrate AI and scale internationally, ECL is paving the way for faster, more efficient advancements in biotech and pharmaceuticals.

Liquidia’s L606 is a clear bet that the next leap in inhaled pulmonary hypertension therapy will come from making treprostinil easier to sustain, not from reinventing the molecule. The real proof will be whether extended exposure translates into better titration, adherence, and durable outcomes in everyday clinical use.

Symvess signals a shift in vascular repair from permanent synthetic grafts toward acellular, tissue engineered conduits designed for host remodeling. By retaining an extracellular matrix “tissue frame,” the approach aims to support integration while reducing long-term foreign body complications. FDA approval makes this a validated clinical category, not just an experimental idea. The key questions now are consistency across real-world patients and sites, and long-horizon durability once remodeling is established.

Vascular implants are shifting from permanent synthetic grafts to biorestorative scaffolds that are replaced by the patient’s own tissue. Xeltis is leading this trend, with its aXess EU hemodialysis trial (120 patients, 18 sites) showing strong patency and low complications across 15,000 plus dialysis sessions. The key unknowns are real world consistency and long term failure modes after the scaffold fully resorbs.

Caregiving often feels overwhelming not from personal failure, but because current systems aren't designed to support the immense operational burden involved. CareCircle addresses this by offering a patient-contextual AI caregiving agent that retains crucial information, helping caregivers manage complex tasks more efficiently. This crucial system support allows caregivers to reduce mental clutter, plan better, and stay engaged in their lives without constant guilt or burnout.

Healthcare data is not just another category of personal information. It is the most sensitive, most permanent and most ethically challenging form of data any organisation can ever handle. Under India’s DPDP Act, this places hospitals, diagnostics, insurers, TPAs, healthtech platforms and researchers in the highest risk bracket. Clinical records create lifelong consequences when breached. Biomedical research depends on continuous data flows that must now comply with stricter rules. Hospitals and insurers operate in massive, interconnected digital ecosystems where a single weak link can expose entire patient histories. Public health programmes need data at population scale, yet DPDP demands that individual rights remain protected. The healthcare sector faced some of the harshest penalties under GDPR in Europe even with a longer preparation window. India’s timeline is shorter. The risk is higher. And the stakes are far more human. If there is one sector that cannot afford to delay DPDP readiness, it is healthcare.